DSIP
A peptide discussed for sleep-related and neuroregulatory interest, though its evidence base is far less concrete than vendor listings suggest.
Also referenced as: Delta Sleep-Inducing Peptide
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when DSIP crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
This profile is grouped by its dominant research area, not by vendor shelf placement.
Delta Sleep-Inducing Peptide
No FDA label signal · 0 trials · 462 PubMed results
Current evidence for DSIP is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
DSIP has no clinical trials that name it and 462 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What DSIP is
DSIP stands for delta sleep-inducing peptide. It has been part of peptide and nootropic discussions for years, usually framed around sleep quality, stress, or neuroregulatory effects.
Why it matters
It is a good example of a compound with strong market persistence despite limited mainstream clinical presence. That makes it useful for understanding how peptide demand and evidence often move at different speeds.
Regulatory context
DSIP is not an FDA-approved sleep medicine in the United States. It should be treated as a research-market entry.
Practical reading note
This is one of the categories where vendor popularity can easily outrun evidence clarity, so careful skepticism is warranted.